0001769804
false
0001769804
2023-08-07
2023-08-07
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date
of report (Date of earliest event reported): August 7, 2023
AUGMEDIX,
INC.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-40890 |
|
83-3299164 |
(State
or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(I.R.S.
Employer
Identification No.) |
111
Sutter Street, Suite 1300, San Francisco, California 94104
(Address
of principal executive offices) (Zip Code)
Registrant’s
telephone number, including area code: (888) 669-4885
N/A
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
☐ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock, $0.0001 par value per share |
|
AUGX |
|
The Nasdaq
Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
2.02. Results of Operations and Financial Condition.
On
August 7, 2023, Augmedix, Inc., a Delaware corporation (the “Company”), released its financial results for
the second quarter ended June 30, 2023. The press release announcing the release of financial results is furnished as Exhibit 99.1 and
is incorporated herein by reference.
The
information provided in this Item 2.02, including Exhibit 99.1, is intended to be “furnished” and shall not be deemed “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise
subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities
Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item
9.01. Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
AUGMEDIX,
INC. |
|
|
|
Dated:
August 7, 2023 |
By:
|
/s/
Paul Ginocchio |
|
|
Paul
Ginocchio |
|
|
Chief
Financial Officer |
2
Exhibit 99.1
Augmedix Delivers 47% Revenue Growth and Expanded
Gross Margins for Second Quarter of 2023
SAN FRANCISCO, August 7, 2023 – Augmedix
(Nasdaq: AUGX), a healthcare technology company that delivers industry-leading ambient medical documentation and data solutions to healthcare
systems, physician practices, hospitals, and telemedicine practitioners, today reported financial results for the three and six months
ended June 30, 2023.
“This
was another strong quarter for Augmedix, as we continue to solidify our position within the burgeoning ambient medical documentation market,”
commented Manny Krakaris, Chief Executive Officer at Augmedix. “We set records for revenue, growing 47% year-over-year, and dollar-based
net revenue retention at 148%, demonstrating that health systems and clinicians increasingly value and are adopting our products. We also
expanded gross margins by 330 basis points to 47.0% as we realize the inherent leverage of our recurring revenue model with our increasing
scale of operations.”
Continued Mr. Krakaris, “Augmedix’s
products are resonating with clinicians due to their ability to generate accurate medical notes while providing high levels of transparency
and control. Our customers also value the breadth of our product portfolio and their ability to toggle across our product lineup to best
match the particular needs of a given patient encounter. We are seeing growing adoption of Augmedix Notes among our largest customers,
and high interest for Augmedix Go, which is currently being tested with multiple customers in the ambulatory setting and with HCA Healthcare
in the acute care setting, and is on track to be launched commercially later this year.”
Concluded Mr. Krakaris, “Looking ahead,
with the structured data that we capture at the point of care, Augmedix is in a unique position to offer even greater value to the healthcare
ecosystem that transcends the patient encounter. We are moving swiftly to deliver innovative data solutions that will help remove systemic
inefficiencies in healthcare billing and reimbursement. We are excited about the future of Augmedix as a platform that will appeal to
several constituents within the industry.”
Second Quarter 2023 Financial
and Operational Highlights
All comparisons, unless otherwise
noted, are to the three months ended June 30, 2022.
| ● | Total revenue was $10.8 million, an increase of 47% compared to $7.3 million. |
| ● | Dollar-based Net Revenue Retention was 148% for Health Enterprise customers compared to 131% in the second quarter of 2022 and 136%
in the first quarter of 2023. |
| ● | Average Clinicians in Service grew 48%. |
| ● | GAAP Gross Margin increased 330 basis points to 47.0% compared to 43.7%. |
| ● | GAAP Operating Expenses were $10.0 million, up 9% compared to $9.1 million. |
| ● | GAAP Net Loss narrowed to $5.0 million compared to $7.3 million. |
| ● | EBITDA losses declined to $4.2 million compared to $6.7 million. Adjusted EBITDA losses declined to $3.6 million compared to $5.1
million, which excludes stock-based compensation in both periods and a loss on debt extinguishment. Adjusted EBITDA losses again declined
sequentially from $4.1 million in the first quarter of 2023. |
| ● | Cash, cash equivalents, and restricted cash were $25.3 million as of June 30, 2023, compared to $22.0 million as of December 31, 2022. |
| ● | Bolstered financial strength via multiple previously announced balance sheet initiatives, including the $12 of million new equity
from HCA Healthcare and Redmile Group LLC, the extension of the term loan facility and interest-only period by up to 18 months, and the
finalization of the $5 million equity line of credit. |
| ● | Established AI Advisory Council to demonstrate Augmedix’s commitment to responsible product development. |
Non-GAAP
operating expenses, EBITDA and Adjusted EBITDA are a Non-GAAP financial measure. Please see “Non-GAAP Financial Measures”
below and the Reconciliation of the GAAP to Non-GAAP Financial Measures table below in this press release.
2023
Revenue Guidance
Augmedix now expects at least $43.5 million of
revenue in 2023.
Conference Call
Augmedix will host a conference call at 1:30 p.m.
PT / 4:30 p.m. ET on Monday, August 7, 2023, to discuss its second quarter 2023 financial results. The conference call can be accessed
by dialing +1-877-407-3982 for U.S. participants or +1-201-493-6780 for international participants and referencing conference ID #13740298.
Interested parties may access a live and archived webcast of the event on the “Investor Relations” section of the Company’s
website at: ir.augmedix.com.
Definition of Key Metrics
Dollar-Based Net Revenue Retention: We
define a “Health Enterprise” as a company or network of doctors that has at least 50 clinicians currently employed or affiliated
that could utilize our services. Dollar-based net revenue retention is determined as the revenue from Health Enterprises as of twelve
months prior to such period end as compared to revenue from these same Health Enterprises as of the current period end, or current period
revenue. Current period revenue includes any expansion or new products and is net of contraction or churn over the trailing twelve months
but excludes revenue from new Health Enterprises in the current period. We believe growth in dollar-based net revenue retention is a key
indicator of the performance of our business as it demonstrates our ability to increase revenue across our existing customer base through
expansion of users and products, as well as our ability to retain existing customers.
Clinicians in Service: We define a clinician
in service as an individual doctor, nurse practitioner or other healthcare professional using our services. We
average the month-end number of clinicians in service for all months in the measurement period and the number of clinicians in service
at the end of the month immediately preceding the measurement period. We believe growth in the number of clinicians in service
is an indicator of the performance of our business as it demonstrates our ability to penetrate the market and grow our business.
About Augmedix
Augmedix
(Nasdaq: AUGX) delivers industry-leading, ambient medical documentation and data solutions to healthcare systems, physician practices,
hospitals, and telemedicine practitioners. Augmedix is on a mission to help clinicians and patients form a human connection at the point
of care with unobtrusive technology. Augmedix’s proprietary Notebuilder Platform extracts relevant data from natural clinician-patient
conversations and converts that data into medical notes in real time, which are seamlessly transferred to the EHR. The company’s
platform uses automatic speech recognition, natural language processing, including large language models, and medical documentation specialists
to generate accurate and timely medical notes. Leveraging this platform, Augmedix’s products relieve clinicians of administrative
burden, in turn, reducing burnout and increasing both clinician and patient satisfaction. Augmedix is also leading the revolution in transforming
point-of-care information into valuable structured data that can drive lower revenue cycle management costs, higher reimbursement levels
and deliver important clinical feedback to the point of care. Augmedix is headquartered in San Francisco, CA, with offices around the
world. To learn more, visit www.augmedix.com.
Non-GAAP Financial Measures
To supplement our consolidated financial statements,
which are prepared and presented in accordance with GAAP, we use the following non-GAAP financial measures: Non-GAAP gross profit, Non-GAAP
gross margin, Non-GAAP Operating Expenses, EBITDA, and adjusted EBITDA. The presentation of this financial information is not intended
to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with
GAAP.
We use these non-GAAP financial measures for financial
and operational decision-making and as a means to evaluate period-to-period comparisons. We believe that these non-GAAP financial measures
provide meaningful supplemental information regarding our performance by excluding certain items that may not be indicative of our recurring
core business operating results. We believe that both management and investors benefit from referring to these non-GAAP financial measures
in assessing our performance and when planning, forecasting, and analyzing future periods. These non-GAAP financial measures also facilitate
management’s internal comparisons to our historical performance and liquidity as well as comparisons to our competitors’ operating results.
We believe these non-GAAP financial measures are useful to investors both because (1) they allow for greater transparency with respect
to key metrics used by management in its financial and operational decision-making and (2) they are used by our institutional investors
and the analyst community to help them analyze the health of our business.
There are a number of limitations related to the
use of non-GAAP financial measures. We compensate for these limitations by providing specific information regarding the GAAP amounts excluded
from these non-GAAP financial measures and evaluating these non-GAAP financial measures together with their relevant financial measures
in accordance with GAAP.
For more information on the non-GAAP financial
measures, please see the Reconciliation of GAAP to non-GAAP Financial Measures table in this press release. This accompanying table includes
details on the GAAP financial measures that are most directly comparable to Non-GAAP financial measures and the related reconciliations
between these financial measures.
Forward-Looking Statements
This press
release contains “forward-looking statements” that involve a number of risks and uncertainties. Words such as “believes,”
“may,” “will,” “estimates,” “potential,” “continues,” “anticipates,” “intends,”
“expects,” “could,” “would,” “projects,” “plans,” “targets,” “excited,”
“optimistic,” and variations of such words and similar expressions are intended to identify forward-looking statements. Such
forward-looking statements include, without limitation, statements regarding the Company continuing to solidify its position within
the burgeoning ambient medical documentation market; the Company’s demonstration that health systems and clinicians increasingly
value and are adopting the Company’s products; the Company’s realization of the inherent operating leverage of its recurring
revenue model with its increasing scale of operations; our customers valuing the breadth of our product portfolio; our customers valuing
their ability to toggle across our product lineup; the Company’s seeing growing adoption of Notes among its largest customers, and
high interest for Go which is currently being tested; the timing for the launch of Go; Augmedix being in a unique position to offer even
greater value to the healthcare ecosystem; moving swiftly to deliver innovative data solutions that will help remove systemic inefficiencies
in healthcare billing and reimbursement; the Company’s excitement about Augmedix as a platform that will appeal to several constituents
within the industry; and the Company’s expectations regarding revenues for the full fiscal year 2023. Our
actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including
but not limited to, risks detailed in our most recent Form 10-K filed with the Securities and Exchange Commission on April 17, 2023 as
well as other documents that may be filed by us from time to time with the Securities and Exchange Commission. In particular, the following
factors, among others, could cause results to differ materially from those expressed or implied by such forward-looking statements: our
expectations regarding changes in regulatory requirements; our ability to interoperate with the electronic health record systems of our
customers; our reliance on vendors; our ability to attract and retain key personnel; the competition to attract and retain remote documentation
specialists; anticipated trends, growth rates, and challenges in our business and in the markets in which we operate; our ability to further
penetrate our existing customer base; our ability to protect and enforce our intellectual property protection and the scope and duration
of such protection; developments and projections relating to our competitors and our industry, including competing dictation software
providers, third-party, non-real time medical note generators and real time medical note documentation services; and the impact of current
and future laws and regulations. Past performance is not necessarily indicative of future results. The forward-looking statements included
in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments
will cause our views to change. We undertake no intention or obligation to update or revise any forward-looking statements, whether as
a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing our
views as of any date subsequent to the date of this press release.
Contact Information
Investors:
Matt Chesler, CFA
FNK IR
(646) 809-2183
augx@fnkir.com
investors@augmedix.com
Media:
Kaila Grafeman
Augmedix
pr@augmedix.com
AUGMEDIX, INC.
Condensed Consolidated Statements of Operations
(Unaudited, in thousands except EPS and Average
Clinicians in Service)
| |
Three Months Ended | |
| |
June 30, | |
| |
(unaudited) | |
| |
2023 | | |
2022 | |
Revenue | |
$ | 10,780 | | |
$ | 7,333 | |
Cost of revenue | |
| 5,715 | | |
| 4,131 | |
Gross profit | |
| 5,065 | | |
| 3,202 | |
Operating Expenses | |
| | | |
| | |
General and administrative | |
| 4,760 | | |
| 4,172 | |
Sales and marketing | |
| 2,649 | | |
| 2,320 | |
Research and development | |
| 2,590 | | |
| 2,649 | |
Total operating expenses | |
| 9,999 | | |
| 9,141 | |
Loss from operations | |
| (4,934 | ) | |
| (5,939 | ) |
| |
| | | |
| | |
Other income (expense), net | |
| (99 | ) | |
| (1,396 | ) |
Net loss | |
$ | (5,033 | ) | |
$ | (7,335 | ) |
| |
| | | |
| | |
Weighted Average common stock outstanding | |
| 43,608 | | |
| 37,416 | |
| |
| | | |
| | |
Earnings Per Share | |
$ | (0.12 | ) | |
$ | (0.20 | ) |
| |
| | | |
| | |
Average Clinicians in Service (CIS) | |
| 1,534 | | |
| 1,040 | |
AUGMEDIX, INC.
Condensed Consolidated Balance Sheet
(Unaudited, in thousands)
| |
June 30, | | |
December 31, | |
| |
2023 | | |
2022 | |
Assets | |
| |
Cash, cash equivalents, and restricted cash | |
$ | 25,260 | | |
$ | 21,988 | |
Accounts receivables, net | |
| 9,433 | | |
| 6,354 | |
Other assets | |
| 9,155 | | |
| 5,299 | |
Total assets | |
| 43,848 | | |
| 33,641 | |
| |
| | | |
| | |
Liabilities & Stockholders’ Equity | |
| | | |
| | |
Liabilities | |
| | | |
| | |
Accounts payable | |
$ | 1,604 | | |
$ | 1,563 | |
Deferred revenue | |
| 7,858 | | |
| 7,254 | |
Loan payable | |
| 19,932 | | |
| 15,134 | |
Other liabilities | |
| 10,465 | | |
| 8,224 | |
Total liabilities | |
$ | 39,859 | | |
$ | 32,175 | |
Stockholders’ equity | |
$ | 3,989 | | |
$ | 1,466 | |
Total liabilities & stockholders’ equity | |
$ | 43,848 | | |
$ | 33,641 | |
AUGMEDIX, INC.
Condensed Consolidated Statement of Cash Flows
(Unaudited, in thousands)
| |
Six Months Ended | |
| |
June 30, | |
| |
2023 | | |
2022 | |
Cash flows from operating activities | |
$ | (12,175 | ) | |
$ | (8,856 | ) |
Cash flows from investing activities | |
| (1,480 | ) | |
| (615 | ) |
Cash flows from financing activities | |
| 16,974 | | |
| (1,248 | ) |
Effect of exchange rate changes on cash and restricted cash | |
| (47 | ) | |
| (90 | ) |
Net decrease in cash | |
$ | 3,272 | | |
$ | (10,809 | ) |
Cash, restricted cash, and cash equivalents at the beginning of the period | |
$ | 21,988 | | |
$ | 41,587 | |
Cash, restricted cash, and cash equivalents at the end of the period | |
$ | 25,260 | | |
$ | 30,778 | |
AUGMEDIX, INC.
Reconciliation of GAAP to Non-GAAP Financial
Measures
(Unaudited, in thousands)
| |
Three Months Ended | |
| |
June 30, | |
| |
(unaudited) | |
| |
2023 | | |
2022 | |
Stock Based Compensation Expense | |
| | |
| |
Cost of revenue | |
$ | 27 | | |
$ | 24 | |
General and administrative | |
| 381 | | |
| 344 | |
Sales and marketing | |
| 64 | | |
| 42 | |
Research and development | |
| 93 | | |
| 81 | |
Total stock-based compensation expense | |
$ | 565 | | |
$ | 491 | |
| |
| | | |
| | |
Net loss | |
$ | (5,033 | ) | |
$ | (7,335 | ) |
Interest | |
| 558 | | |
| 385 | |
Tax | |
| 51 | | |
| 2 | |
Depreciation | |
| 262 | | |
| 215 | |
EBITDA | |
$ | (4,162 | ) | |
$ | (6,733 | ) |
Add: Stock-based compensation | |
| 565 | | |
| 491 | |
Add: Loss on extinguishment | |
| - | | |
| 1,097 | |
Adjusted EBITDA | |
$ | (3,597 | ) | |
$ | (5,145 | ) |
| |
| | | |
| | |
GAAP Cost of revenue | |
$ | 5,715 | | |
$ | 4,131 | |
Less: Stock-based compensation | |
| (27 | ) | |
| (24 | ) |
Non-GAAP cost of revenue | |
$ | 5,688 | | |
$ | 4,107 | |
| |
| | | |
| | |
Non-GAAP Gross Profit | |
$ | 5,092 | | |
$ | 3,226 | |
Non-GAAP Gross Margin | |
| 47.2 | % | |
| 44.0 | % |
| |
| | | |
| | |
GAAP Operating expenses | |
$ | 9,999 | | |
$ | 9,141 | |
Less: Stock-based compensation | |
| (538 | ) | |
| (467 | ) |
Non-GAAP operating expenses | |
$ | 9,461 | | |
$ | 8,674 | |
7
v3.23.2
Cover
|
Aug. 07, 2023 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Aug. 07, 2023
|
Entity File Number |
001-40890
|
Entity Registrant Name |
AUGMEDIX,
INC.
|
Entity Central Index Key |
0001769804
|
Entity Tax Identification Number |
83-3299164
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
111
Sutter Street
|
Entity Address, Address Line Two |
Suite 1300
|
Entity Address, City or Town |
San Francisco
|
Entity Address, State or Province |
CA
|
Entity Address, Postal Zip Code |
94104
|
City Area Code |
888
|
Local Phone Number |
669-4885
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common
Stock, $0.0001 par value per share
|
Trading Symbol |
AUGX
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
true
|
Elected Not To Use the Extended Transition Period |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Augmedix (NASDAQ:AUGX)
Historical Stock Chart
From Apr 2024 to May 2024
Augmedix (NASDAQ:AUGX)
Historical Stock Chart
From May 2023 to May 2024